✦ LIBER ✦

573 POSTER Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumors with mutated EGFR

✍ Scribed by R. Plummer; L. Vidal; L. Li; H. Shaw; R. Perrett; M. Shahidi; A. Amelsberg; G. Temple; H. Calvert; J. de Bono

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

703 POSTER A phase I and pharmacokinetic

✍ R. Plummer; L. Vidal; R. Perrett; J. Spicer; P. Stopfer; M. Shahidi; G. Temple; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 64 KB

567 POSTER Efficacy of BIBW 2992, an irr

✍ F. Solca; A. Baum; F. Himmelsbach; A. Amelsberg; G. Adolf 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 60 KB

9166 Activity of BIBW 2992, an irreversi

✍ De Greve, J.; Teugels, E.; Geers, C.; DeMey, J.; in 'tveld, P.; Decoster, L.; Ta 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 65 KB

1417 POSTER A Phase II Trial of Afatinib

✍ E.L. Kwak; G.I. Shapiro; S.M. Cohen; C.R. Becerra; H.J. Lenz; S. Gooden; M. Robo 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

A phase I dose escalation study of BIBW

✍ Eskens, F A L M; Mom, C H; Planting, A S T; Gietema, J A; Amelsberg, A; Huisman, 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 173 KB

Phase I, dose-finding study of AZD8931,

✍ Tjulandin, S.; Moiseyenko, V.; Semiglazov, V.; Manikhas, G.; Learoyd, M.; Saunde 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 313 KB